Value-Based Pricing Working Party #1: Briefing for DH presentation
|
|
- Shawn Terry
- 5 years ago
- Views:
Transcription
1 Value-Based Pricing Working Party #1: Briefing for DH presentation This document provides background material for the DH presentation to the first Working Party on the implementation of value assessment under of Value-Based Pricing (VBP). Rationale for wider value assessment as part of VBP The current process of assessment of new treatments can be thought of as determining whether the benefit to patients of a new technology, measured in QALY 1 gains, are sufficient to offset the losses to patients elsewhere in the NHS when funds are re-allocated to the new treatment, necessitating the withdrawal of other treatments and services. This decision can be effected by ensuring that the incremental costs per QALY gained from the treatment are no more than the incremental cost of generating QALYs elsewhere in the NHS which are reflected, in principle, in the cost per QALY threshold. In principle, this approach will ensure that new treatments do not displace more health gain than they provide, and will lead to decisions which do not diminish the value of benefits gained from the NHS budget, subject to two conditions: i. That all QALYs provided by treatments, or displaced elsewhere in the NHS, ii. are of equal value to society That only patients are affected, through the health gains (or losses) from new (or displaced) treatments and we are not concerned with any impacts on other members of society The rationale for a wider assessment of value as part of VBP is based on the proposition that these conditions do not hold. There is evidence that society places greater value on QALYs provided in some circumstances for example when they are provided to patients in particularly severe health states, or with very high unmet medical need. VBP addresses this prioritisation with a system of weights to reflect the greater societal value of QALYs provided to patients with high Burden of Illness. It is also evident that treatments have impacts beyond their effects on patients. For example, treatments may mean patients are able to return to work or provide care to others, so contributing more to society. They may also need less care, in residential homes or provided by family members, as a result of their treatment. These aspects of treatments have real effects on people which are routinely assessed when considering decisions about other types of public spending. A key objective of VBP is that these Wider Societal Benefits will be measured systematically and their contribution to the value of treatments reflected accordingly. 1 Quality-Adjusted Life Years a universal unit for measuring health impacts 1
2 Terms of Reference for development and implementation of wider value assessment by NICE The methods for value assessment of branded medicines under Value-Based Pricing should: be applied to medicines within the scope of the Value-Based Pricing system, and incorporated into the methods for other categories of guidance at NICE s discretion; adopt the same benefit perspective for all technologies falling within the scope of VBP, and for displaced treatments (1); be as transparent and predictable as possible; be informed by the best available evidence; include a simple system of weighting for Burden of Illness that appropriately reflects the differential value of treatments for the most serious conditions (2); encompass the differential valuation of End of Life treatments in the current approach within the system of Burden of Illness weights; include a proportionate system for taking account of Wider Societal Benefits (3); not include a further weighting for Therapeutic Innovation and Improvement (4); produce guidance for patients and the NHS which describes the clinical and cost effectiveness of the technology and its position in clinical practice. Notes to Terms of Reference (1) That is, the value of a new treatment is considered net of the value of what is displaced, and the valuation methodology is applied consistently across treatments, including where the net value impact in respect of an element of VBP may be negative (2) For example, using a simple percentage weighting that is proportionate to the QALY loss suffered by patients with the condition (3) The perspective adopted for measuring WSBs should, in principle, be as set out in the HMT Green Book for Appraisal and Evaluation in Central Government - which specifies the cross-government approach for evaluating costs and benefits of spending decisions. However in practice it will be important to reflect uncertainties in the evidence for the magnitude of WSBs, the novelty of the approach, and the degree of consensus among stakeholders. Options may in practice include constraining the weight given to different elements of WSBs in the valuation of treatments, or initially taking a selective approach to the types of benefit included in the assessment framework, in order to support incremental broadening of the value perspective. It will be important to ensure that the approach to incorporating WSB is applied systematically and consistently. (4) To ensure that innovation is rewarded only when the technology s use brings extra value. 2
3 Burden of Illness The ToR specify that value assessment in VBP should include a simple system of weighting for Burden of Illness that appropriately reflects the differential value of treatments for the most serious conditions Rationale The QALY calculation methodology ensures, in principle, that QALYs gained by a particular patient are of equal value, regardless of their composition in terms of Quality of Life (QoL) and duration. But society may still legitimately place greater value on QALYs given to patients in different circumstances for example when their conditions are particularly serious. Definition DH has formulated a definition of Burden of Illness which is designed to capture the seriousness of the condition suffered by patients, as well as the degree of unmet need. In this formulation, Burden of Illness is defined as the number of QALYs lost by the patient because of their condition. For example, a patient who died of a condition, while they would have been otherwise expected to live for a further 50 years at 90% QoL, would be deemed to have a Burden of Illness (BoI) of 45 QALYs (90% * 50). Similarly, if a patient s condition did not reduce their life expectancy, but meant their QoL was reduced from 90% to 60% for a period of 5 years, this would correspond with a BoI of 1.5 QALYs (30% * 5). Evidence of societal preferences in respect of Burden of Illness A workshop in November 2012 reviewed a wide range of evidence pertaining to society s preferences in respect of treatments given to patients with different BoI. The summary of that evidence, as interpreted by DH, was that there was reasonable support for the general notion that society put greater value on QALYs provided to patients with higher BoI, as defined above. However the evidence did not dictate a particular weighting mechanism for expressing this differential valuation. Nor did it specify particular levels of relative weighting for QALYs provided to patients with different BoI. The workshop also reviewed evidence in respect of society s prioritisation of treatments on the basis of End of Life that is, in general terms, the proximity of the patient to death. The interpretation of this evidence was that it did not support a separate weighting for End of Life. However the evidence was consistent with the related notion that society put differential weight on treating patients whose condition reduced their life expectancy. This aspect of conditions is encompassed in the definition of BoI, as it results in a loss of QALYs. One interpretation of the evidence that emerged in feedback from workshop participants 3
4 was that society may put a different value on the portion of BoI that results from lost life expectancy, as opposed to loss in QoL. For example, a patient s condition might reduce their QoL from 80% to 50% for 10 years, corresponding to a loss of 3 QALYs, and then cause their premature death, with a loss of 5 QALYs. The total QALY loss, and BoI would be 8 QALYs. But the interpretation above would imply that the two components of loss (3 QALYs in QoL, 5 QALYs in Length of Life (LoL)) would be considered separately for the purposes of valuation in VBP, perhaps with differential weightings and contributions to the assessed value of the treatment. Possible formulation of weighting systems consistent with the evidence and ToR As explained above, the evidence reviewed was not considered to dictate particular weighting systems, or relative weights. However the DH work describes a simple approach to weighting, which may be considered to be consistent with the evidence and the ToR. In this system, treatments are awarded a simple percentage premium for every QALY of BoI. For example, if the premium per QALY of loss (to be applied to all treatments) was 5%, then a treatment for a patient with 6 QALYs of loss would attract a 30% weighting. If the evidence were taken to support a separation of BoI into the QALYs lost through QoL and LoL, then these components might attract different premia. For example, if the premium for QALYs lost in QoL was set at 4%, while that for QALYs lost due through LoL was 6%, then a treatment for a patient losing 2 QALYs in QoL, and 10 QALYs in LoL would be given a weighting of 68% (2*4% + 10*6%). It might also be considered desirable to use a tapering or capping mechanism to limit the total weighting for any given treatment. The details of possible mechanisms will be explored further in the Working Party meeting considering BoI. It is important to note that when a new treatment is funded, other treatments elsewhere in the NHS must be displaced and these treatments will also be associated with BoI. The ToR require that decisions on funding new treatments fully reflect the value of treatments displaced. This implies calculating the BoI weighting for the notional displaced QALYs that are lost when funds are re-allocated to a new treatment. This important aspect of VBP is described in more detail below. 4
5 Wider Societal Benefits The ToR specify that the value assessment mechanism in VBP should include a proportionate system for taking account of Wider Societal Benefits Perspective for Value Assessment in VBP The ToR further define the perspective of value assessment to be that set out in the Treasury Green Book 2, which provides a common, cross-government approach to evaluating the costs and benefits of decision making in respect of public funds. The Green Book states that The relevant costs and benefits to government and society of all options should be valued, and the net benefits or costs calculated. and Relevant costs and benefits are those that can be affected by the decision at hand. In respect of funding decisions for health treatments, this perspective implies that, as well as health impacts and NHS costs, value assessment should include other impacts on society. This represents an important change in the perspective adopted in the NICE technology appraisal process. For the purposes of value assessment in VBP, DH has developed a systematic approach to defining and measuring WSBs that is consistent with this perspective, and is available for NICE to potentially use in implementing VBP. Definition of Wider Societal Benefits (WSBs) The approach to reflecting WSBs in value assessment is founded on the principle that any resources a patient contributes or produces, net of resources they utilise or consume, is available for others in society to use and benefit from. Similarly, if a patient utilises or consumes resources in excess of the resources they contribute or produce, then those resources must inevitably be provided by society, and are not available for others to consume and benefit from. This concept of net resource contribution the patient s production of resources net of their consumption of resources provides a definition of the patient s WSBs. If a treatment changes the production or consumption of resources by a patient, then it will change the amount of resources available for others to benefit from having an impact on WSBs. For example, suppose a patient with a particular condition produced 1500 worth of resources per month through their labour, paid or unpaid. If they consumed 1000 of 2 5
6 resources per month, for instance in the normal goods and services used in everyday life, but possibly also by needing social care, or informal care by family then, in this perspective, they would be judged to provide a net resource contribution worth 500 per month. Suppose that a treatment improves the patient s health, such that they now contribute 1600 worth of resource per month. This increased amount might reflect the fact that they are able to work more. They may also utilise fewer resources, perhaps because they require less care by their family. Suppose they now consume resources worth 900 per month, giving a net resource contribution of 700 per month. This would imply that the effect of the treatment was to increase the patient s net resource contribution by 200 per month. If the duration of the treatment s effects was 5 months, the total impact on net resource contribution and the WSBs ascribed to the treatment would be Categorisation of WSBs For convenience, the production and consumption of resources by the patient are divided into sub-categories. For production these are Paid production that is, labour provided for a salary or other payment Unpaid production including domestic work, child care and volunteering For consumption these are Formal care social care paid for by the patient, their family or Government Informal care including care provided by family and friends Private paid consumption including goods and services used in everyday life, such as housing, food, clothes, travel and entertainment Private unpaid consumption utilisation of unpaid production, as above Government consumption using services provided directly by Government, including education and health services (but excluding those directly related to the condition in question) Estimating WSBs for patients in different health states The DH work to date includes a mechanism by which each element of WSBs and therefore the total amount of WSBs can be estimated for a patient, given their Age Gender Type of health condition - defined according to the International Classification of Disease (ICD) 6
7 QoL score (on a scale in which 100% represents full health, and 0% is considered equivalent to death) So, for example, a female patient aged 30 with diabetes (ICD = M) and QoL of 90% might be estimated to generate 1600 worth of WSBs (net resources contributed) per month (illustrative figures). This sum is composed of the elements of production and consumption set out above. Each element is calculated using data and modelling from a variety of sources some existing datasets, as well as analysis that has been specifically carried out or commissioned to support the development of an approach to measuring WSBs as part of VBP. The details of this analysis, and the underlying data, assumptions and modelling, will be presented at a future Working Party. Implementation in appraisals The mechanism described above allows the WSB rate for a single patient to be calculated, given only the four inputs of age, gender, ICD and QoL. In principle it is straightforward to use this calculation to estimate the WSBs provided by a treatment by comparing the progression of patients diseases over time with the treatment and its comparator, and calculating the net change in WSBs in exactly the same way as QoL profiles over time are used to calculate incremental QALY gains. However there are practical difficulties associated with integrating WSB calculation in the cost-effectiveness models that are currently used to calculate the incremental QALY gains from treatments. In particular, production of WSBs is highly non-linear with respect to age. It is important, therefore, to use a full representation of the distribution of patients in the expected treatment population to calculate WSBs. This data may not always be available in current submissions to NICE. To address this issue, a simple default calculation mechanism has been developed which provides an estimate of the WSBs associated with a treatment without imposing burdens on companies and appraisal committees. In this approach, a reference dataset is used which includes all the information required to calculate the WSBs (expressed per QALY of health gain) provided by typical treatments in each of 1284 diseases (ICDs). Given knowledge of the indicated ICD, this dataset can therefore be used to calculate (or look up) the estimated WSBs per QALY of health gain. For example, treatments of rheumatoid arthritis (ICD M06) are provisionally estimated, based on the inputs from the reference dataset, to provide 43,200 worth of WSBs for each QALY of health gain. If a new drug for this condition provides 0.2 QALYs, it would therefore be estimated to provide 8,640 of WSBs. The accuracy of the above estimate will depend on the degree to which the reference dataset is representative of the actual treatment population. The mechanism has therefore 7
8 be designed such that the face-validity of the estimate, and each of its components, can easily be verified by comparing the profile in the reference dataset with any information the company may provide on the actual treatment population. Where evidence shows that the reference dataset is not representative, this data can simply be entered into the calculation to give a more accurate estimate of the WSBs generated. Comparing new and displaced treatments in VBP When funds are re-allocated to a new treatment they are necessarily unavailable for some other use in the NHS. This means patients elsewhere will have treatments withdrawn, and will suffer health losses as a result. This sacrifice of patient health is reflected in the cost per QALY threshold. However the loss of health elsewhere due to the displacement of treatments implies that WSBs will also be lost elsewhere. The QALYs displaced will also be associated with some level of BoI. The ToR specifically require that value assessment should adopt the same benefit perspective for all technologies falling within the scope of VBP, and for displaced treatments Any WSB gains attributed to new treatments must therefore be calculated net of any WSB losses displaced elsewhere. The BoI associated with displaced QALYs must also be estimated and reflected in value assessment. For example, suppose a treatment provided 2 QALYs of health gain, and displaced 2 QALYs elsewhere (i.e. its cost per QALY was exactly at the threshold). The new treatment might be associated with 12,000 of WSBs, but the QALYs displaced would also be associated with WSBs. If 8,000 of WSBs were displaced, then the net impact, and the value of the benefit to society, would be 2,000. Note that it is possible the net WSB impact could be negative and treatments could displace more WSBs than they provide. The 2 QALYs gained might be associated with a BoI weighting of +50%, meaning they were assigned a value of 3 QALYs (2 QALYs + (2 QALYs*50%)). But this must be compared to the weighting on QALYs displaced. If this was +60%, then the QALYs displaced would be accorded a value of 3.2 weighted QALYs. Applying the wider value perspective to displaced treatments requires that the notional displaced QALY is characterised in terms of its associated BoI and WSBs. This has been achieved, using empirical data showing how a notional displaced QALY is distributed across the 1284 diseases in the reference dataset described above. The BoI and WSBs for each disease can be calculated, giving a weighted average BoI and WSB estimate for the notional displaced QALY, which can be compared to the BoI and WSBs associated with QALYs gained from new treatments. This calculation will be explained in detail at future working parties. There are a number of ways in which the BoI and WSBs associated with QALYs gained and displaced can be used to inform NICE decisions. An approach will be described in which the 8
9 cost per QALY threshold to be applied to a particular product is adjusted to reflect its BoI and WSBs relative to those of displaced QALYs. Equalities Widening the scope of value consideration could have impacts on equalities, as treatments for some groups in society may be associated with levels of BoI or WSBs that vary systematically from the average implying higher or lower value under the new system. These important impacts have been considered in detail in a workshop held by DH. Some important aspect of the potential equalities impact are set out here as context. First, it is important to note that changes in the valuation of treatments do not necessarily imply changes in access to treatments which would have an impact on equalities. If companies provide access to new products under VBP in the same way they would under the current system, and the same products are made available to patients albeit at different prices then the most likely outcome is that there is no impact on equalities. Second, if there is a change in access, the ultimate impacts on equalities may not be consistent with the most obvious intuition. For example, older patients tend to use more formal care resources, which impose a cost on society 3. However if treatments improve the health of such patients, this may mean they need less formal care implying potentially large gains in value, because the patients are now using less of society s resources, even though they are much less likely to be contributing to society through paid employment. Furthermore, if reflecting attributes such as WSBs results in re-allocation of resources to treatments which provide the greatest additional benefit beyond health, there will be a value dividend to society, for example in greater tax revenues. Any such change will always have varied impacts, both positive and negative, on individuals. But overall, groups of people such as older people - which may receive less health resource would be expected to share in this dividend, for example through increased provision of public services. The share of the dividend that benefits these groups could potentially offset, at least in part, any direct reduction in access to treatments. The equality impact of these measures therefore requires careful consideration, and this will be part of the ultimate evaluation of this aspect of VBP. Finally, it is important to note that while NICE, and all public organisations, have an obligation to understand the possible equality impacts of their actions, and to take any reasonable measures to mitigate such impacts where that is considered appropriate, they are not prevented from taking actions to achieve legitimate goals even if these have differential effects on different groups. 3 It is worth noting that the effect of these costs would likely be borne, ultimately, by other users of formal care resources, if the budgets for providing this care are limited 9
Value based pricing for the NHS
Value based pricing for the NHS Karl Claxton Department of Economics and Related Studies, Centre for Health Economics, University of York. www.york.ac.uk/inst/che Some key questions What is value in the
More informationQuality of Health Care and the Design of the Basic Benefit Package Lessons from Overseas
Quality of Health Care and the Design of the Basic Benefit Package Lessons from Overseas Michael Drummond Centre for Health Economics, University of York Outline of Presentation Efficiency and the use
More informationCASE COMMENTS. Introduction
208 CASE COMMENTS The UK Pharmaceutical Price Regulation Scheme (PPRS) and the Statutory Regulations: An Overview and Outline of How the Schemes May Impact the Life Sciences Industry CHRISTIAN HILL,* PAUL
More informationEstimating the costs of health inequalities
Estimating the costs of health inequalities A report prepared for the Marmot Review February 2010 Ltd, London. Introduction Sir Michael Marmot was commissioned to lead a review of health inequalities in
More informationImpact Assessment (IA)
Title: 2018 Statutory Scheme Branded Medicines Pricing IA No: 9553 Lead department or agency: Department of Health and Social Care Other departments or agencies: N/A Impact Assessment (IA) Date: 12/07/2018
More informationNICE and NHS England consultation on changes to the arrangements for evaluating and funding drugs and other health
NICE and NHS England consultation on changes to the arrangements for evaluating and funding drugs and other health technologies assessed through NICE s technology appraisal and highly specialised technologies
More informationCHILDREN S SAVINGS OPTIONS FOR A FUTURE ACCOUNT ISSUES PAPER
CHILDREN S SAVINGS OPTIONS FOR A FUTURE ACCOUNT ISSUES PAPER RESPONSE FROM TISA October 2010 CHILDREN S SAVINGS OPTIONS FOR A FUTURE ACCOUNT ISSUES PAPER TISA is the key Association supporting Children
More informationINTO ESTIMATES OF COST PER QALY: November Allan Wailoo, Professor of Health Economics
INCORPORATING WIDER SOCIETAL BENEFITS INTO ESTIMATES OF COST PER QALY: IMPLICATIONS OF VALUE BASED PRICING FOR NICE. REPORT BY THE DECISION SUPPORT UNIT November 2012 Allan Wailoo, Professor of Health
More informationThis is a repository copy of Pharmaceutical Pricing : Early Access, The Cancer Drugs Fund and the Role of NICE.
This is a repository copy of Pharmaceutical Pricing : Early Access, The Cancer Drugs Fund and the Role of NICE. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/103088/ Version:
More informationThe ICER Value Framework: The Importance of Empirical Estimates of Opportunity Costs
The ICER Value Framework: The Importance of Empirical Estimates of Opportunity Costs Steven D. Pearson, MD, MSc The ICER Value Framework Takes a population level perspective as opposed to trying to serve
More informationEvaluating the value of new drugs
Evaluating the value of new drugs The ICER value framework The framework includes Content A list of elements to consider Measurement options Methods to measure or judge each element Assessment process
More informationIs there additional value attached to health gains at the end-of-life? A re-visit
COHERE - Centre of Health Economics Research Is there additional value attached to health gains at the end-of-life? A re-visit By Dorte Gyrd-Hansen, COHERE, Department of Business and Economics & Department
More informationMedical Research: What s it worth? Estimating the economic benefits from medical research in the UK
Medical Research: What s it worth? Estimating the economic benefits from medical research in the UK Briefing November 2008 Summary This briefing describes the outcomes of a one-year study into the economic
More informationIntroduction to Pharmacoeconomics. Almut G. Winterstein, Ph.D.
Introduction to Pharmacoeconomics Almut G. Winterstein, Ph.D. Why do we need Health Economics? Suppose you are comparing two drugs or services where one is more expensive than the other. In choosing the
More informationStep by step guide to economic evaluation in cancer trials
What is CREST? The Centre for Health Economics Research and Evaluation (CHERE) at UTS has been contracted by Cancer Australia to establish a dedicated Cancer Research Economics Support Team (CREST) to
More informationREVIEW OF PENSION SCHEME WIND-UP PRIORITIES A REPORT FOR THE DEPARTMENT OF SOCIAL PROTECTION 4 TH JANUARY 2013
REVIEW OF PENSION SCHEME WIND-UP PRIORITIES A REPORT FOR THE DEPARTMENT OF SOCIAL PROTECTION 4 TH JANUARY 2013 CONTENTS 1. Introduction... 1 2. Approach and methodology... 8 3. Current priority order...
More informationCIH Briefing on the White Paper for Welfare Reform. Universal Credit: welfare that works
CIH Briefing on the White Paper for Welfare Reform Universal Credit: welfare that works November 2010 1) Introduction The government has published its White Paper on welfare reform which sets out its proposals
More informationThe impact of tax and benefit reforms by sex: some simple analysis
The impact of tax and benefit reforms by sex: some simple analysis IFS Briefing Note 118 James Browne The impact of tax and benefit reforms by sex: some simple analysis 1. Introduction 1 James Browne Institute
More informationHousehold Benefit Cap. Equality impact assessment March 2011
Household Benefit Cap Equality impact assessment March 2011 Equality impact assessment for household benefits cap Brief outline of the policy or service 1. From 2013 the Government will introduce a cap
More informationInvestigation into the Cancer Drugs Fund
Report by the Comptroller and Auditor General Department of Health and NHS England Investigation into the Cancer Drugs Fund HC 442 SESSION 2015-16 17 SEPTEMBER 2015 4 Key facts Investigation into the Cancer
More informationCommissioning for Quality and Innovation (CQUIN)
Commissioning for Quality and Innovation (CQUIN) Guidance for 2017-2019 Publications Gateway Reference 07725 March 2018 www.england.nhs.uk Contents Section Slide 1.0 Introduction 3 2.0 Clinical quality
More informationChanges in the regulatory environment: The EU economic assessment study
Changes in the regulatory environment: The EU economic assessment study Dr Peter Varnai Technopolis Group 8 February 2018 Introduction Present the independent study of the economic impact of the Paediatric
More informationSimplifying the Formal Structure of UK Income Tax
Fiscal Studies (1997) vol. 18, no. 3, pp. 319 334 Simplifying the Formal Structure of UK Income Tax JULIAN McCRAE * Abstract The tax system in the UK has developed through numerous ad hoc changes to its
More informationICER Value Assessment Framework: 1.0 to 2.0
ICER Value Assessment Framework: 1.0 to 2.0 Outline Background on ICER Version 1.0 development Conceptual basis for ICER value assessment framework Domains of value Long-term perspective (value for money)
More informationCashability Discussion paper
Cashability Discussion paper Version Number 1 Date 27/3/15 CONTENTS 1 Purpose... 3 2 Definition... 3 3 Practical issues involved in cashing a benefit... 4 4 Making resources more cashable... 5 5 Strategic
More informationPensions tax planning for high earners
KEY GUIDE Pensions tax planning for high earners The rising tax burden on income If you feel you re paying more and more tax, you are not alone. More than one in seven of income tax payers are taxed at
More informationIs the QALY a Necessary Evil? Michael Drummond Centre for Health Economics, University of York
Is the QALY a Necessary Evil? Michael Drummond Centre for Health Economics, University of York Outline of Presentation Some background. What s good about the QALY? What adjustments are required to QALYs?
More informationNagement. Revenue Scotland. Risk Management Framework
Nagement Revenue Scotland Risk Management Framework Table of Contents 1. Introduction... 2 1.2 Overview of risk management... 2 2. Policy statement... 3 3. Risk management approach... 4 3.1 Risk management
More information3.2. CCG Board Paper Summary Sheet. Agenda Item. DETAILS Part 1 (Open) X Part 2 (Closed) Title of Paper Pharmaceutical Rebate Schemes Meeting
CCG Board Paper Summary Sheet 3.2 DETAILS Part 1 (Open) X Part 2 (Closed) Agenda Item Title of Paper Pharmaceutical Rebate Schemes Meeting CCG Board Date 5 st November 2015 Executive Lead Dawn Clarke,
More informationNew approaches to mortgage market regulation
New approaches to mortgage market regulation The impact of the MMR and the risks and benefits for consumers, society and the wider economy Supplementary material on mortgage affordability, the role of
More informationSocial costs tend to persist over a person s lifetime while most tangible costs are one-off
Social costs tend to persist over a person s lifetime while most tangible costs are one-off 2. The social impact of natural disasters Key points The total economic cost of natural disasters is a complex
More informationHousehold Benefit Cap. Equality impact assessment October 2011
Household Benefit Cap Equality impact assessment October 2011 Equality impact assessment for household benefits cap Brief outline of the policy or service 1. From 2013 the Government will introduce a cap
More informationPensions and tax planning for high earners TAX PLAN ~~~~~~~~ ~~~~~~~~~ ~~~~~~~~~~~~~~ ~~~~~~~~~ Key Guide
Pensions and tax planning for high earners TAX PLAN ~~~~~~~~ ~~~~~~~~~ ~~~~~~~~~~~~~~ ~~~~~~~~~ Key Guide The rising tax burden on income If you are a high-earner and feel you are paying more and more
More informationNHS Trade Union response to HMT consultation on reforms to public sector exit payments.
NHS Trade Union response to HMT consultation on reforms to public sector exit payments. Introduction & general comments We are unclear from the consultation the extent to which Government wishes to impose
More informationCivil Justice Council response to Ministry of Justice consultation paper Fee Remissions for the Courts & Tribunals
Civil Justice Council response to Ministry of Justice consultation paper Fee Remissions for the Courts & Tribunals Introductory remarks There are many aspects about this consultation which have caused
More informationRaphael Wittenberg LONG-TERM CARE FOR OLDER PEOPLE: ECONOMIC ISSUES. Myers JDC Brookdale Institute, Jerusalem 25 December 2013
LONG-TERM CARE FOR OLDER PEOPLE: ECONOMIC ISSUES Raphael Wittenberg Personal Social Services Research Unit, LSE Centre for Health Services Economics & Organisation, Oxford Myers JDC Brookdale Institute,
More informationPension tax planning for high earners
KEY GUIDE Pension tax planning for high earners KEY GUIDE January 2019 Pensions tax planning for high earners 2 Introduction MITIGATING A GROWING TAX BILL If you are a high-earner and feel you are paying
More informationKEY GUIDE. Pensions tax planning for high earners
KEY GUIDE Pensions tax planning for high earners The rising tax burden on income If you feel you are paying more and more tax, you are not alone. More than one in seven of income tax payers are taxed at
More informationAssociation of NHS Charities Members Forum The Regulation and Governance of NHS Charities - Consultation Response. Paul Whitbourn 5 March 2014
Association of NHS Charities Members Forum The Regulation and Governance of NHS Charities - Consultation Response Paul Whitbourn 5 March 2014 Consultation Overview A review of regulation and governance
More informationUniversal Credit Budgeting Advances. Equality impact assessment October 2011
Universal Credit Budgeting Advances Equality impact assessment October 2011 Equality impact assessment for Universal Credit Budgeting Advances Consultation and involvement 1. A formal consultation was
More informationBenefits of reducing health inequalities
Benefits of reducing health inequalities Summary The benefits of reducing health inequalities are economic as well as social. The cost of health inequalities can be measured in both human terms, lost years
More informationPUBLIC HEALTH PROGRAMME GUIDANCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE PUBLIC HEALTH PROGRAMME GUIDANCE SCOPE 1 Guidance title Guidance for primary care services and employers on the management of long-term sickness and
More informationCCG Policy on Primary Care Rebate Schemes (PCRS)
CCG Policy on Primary Care Rebate Schemes (PCRS) 1. Introduction A number of manufacturers have established rebate schemes for drugs used in primary care. Their motive for this could be speculated on for
More informationMethodology to assess the cost impact of PMB benefit definitions
Methodology to assess the cost impact of PMB benefit definitions Version 1.0.0 07 March 2012 Contents 1 Background... 1 2 Aim... 1 3 Objectives... 1 4 Methods... 2 5 Variables for data collection, data
More informationHealth resource tracking is the process of measuring health spending and the flow
System of Health Accounts 2011 What is SHA 2011 and How Are SHA 2011 Data Produced and Used? Health resource tracking is the process of measuring health spending and the flow of financial resources among
More informationLocal Government Pension Scheme (England and Wales) Actuarial valuation as at 31 March 2013 Advice on assumptions
Date: 2 February 2015 Authors: Ian Boonin FIA Michael Scanlon FIA Contents page 1 Executive summary 1 2 Introduction 7 3 General considerations 10 4 Pensioner mortality 12 5 Age retirement from service
More informationOverview of Pharmaco- Economics Methodologies Maher Hassoun, M.S.
Overview of Pharmaco- Economics Methodologies Maher Hassoun, M.S. Director of Communications, ISPOR Lebanon Chapter (LSPOR) ISPOR Member Country Manager, Mundipharma Lebanon and Jordan Outline Current
More informationDAMAGES (INVESTMENT RETURNS AND PERIODICAL PAYMENTS) (SCOTLAND) BILL
DAMAGES (INVESTMENT RETURNS AND PERIODICAL PAYMENTS) (SCOTLAND) BILL FINANCIAL MEMORANDUM INTRODUCTION 1. As required under Rule 9.3.2 of the Parliament s Standing Orders, this Financial Memorandum is
More informationEvaluating the Value of New Drugs and Devices
Evaluating the Value of New Drugs and Devices Copyright ICER 2015 The ICER Value Framework The problems the value framework was intended to address Poor reliability and consistency of value determinations
More informationDecember 20, Re: Notice of Benefit and Payment Parameters for 2015 proposed rule. To Whom it May Concern,
December 20, 2013 Centers for Medicare & Medicaid Services U.S. Department of Health and Human Services Attention: CMS-9954-P Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, DC 20201
More informationImpact Assessment (IA)
Title: Abolition of Assessed Income Periods for Pension Credit IA No: Lead department or agency: Department for Work and Pensions Other departments or agencies: Impact Assessment (IA) Date: October 2013
More informationNagement. Revenue Scotland. Risk Management Framework. Revised [ ]February Table of Contents Nagement... 0
Nagement Revenue Scotland Risk Management Framework Revised [ ]February 2016 Table of Contents Nagement... 0 1. Introduction... 2 1.2 Overview of risk management... 2 2. Policy Statement... 3 3. Risk Management
More informationSummary of consultation feedback:
Summary of consultation feedback: Future funding of supported housing 20 December 2017 Summary of key points: This briefing summarises the feedback we have received from housing associations to date on
More informationPensions and tax planning for high earners
KEY GUIDE Pensions and tax planning for high earners The rising tax burden on income If you find more and more of your income is taxed at over the basic rate, you are not alone. The point at which you
More informationFinancing a High-Performing Chronic Care System in Singapore. Donald Low Associate Dean (Executive Education) LKY School of Public Policy, NUS
Financing a High-Performing Chronic Care System in Singapore Donald Low Associate Dean (Executive Education) LKY School of Public Policy, NUS Driving Forces in Financing Chronic Care 1. Ageing demographics
More informationACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS. Supporting employees and building sustainable drug plans...together
ACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS Supporting employees and building sustainable drug plans...together Not available in the province of Quebec INTRODUCING THE SPECIALTY DRUG PROGRAM If you
More informationRisk Management Procedure. Version Number: 6.0 Controlled Document Sponsor: Controlled Document Lead:
Risk Management Procedure CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Procedure Governance To detail the procedure for the management of risk 419 Version Number: 6.0
More informationCare Act first-phase reforms
Report by the Comptroller and Auditor General Department of Health Care Act first-phase reforms HC 82 SESSION 2015-16 11 JUNE 2015 Care Act first-phase reforms Summary 5 Summary 1 Social care is personal
More informationCitizens Health Care Working Group. Greenville, Mississippi Listening Sessions. April 18, Final Report
Citizens Health Care Working Group Greenville, Mississippi Listening Sessions Final Report Greenville, Mississippi Listening Sessions Introduction Two listening sessions were held in Greenville, MS, on.
More informationAct on Mandatory Pension Insurance and on the Activities of Pension Funds. No. 129, 23 December 1997
Act on Mandatory Pension Insurance and on the Activities of Pension Funds No. 129, 23 December 1997 Process before the Athingi. Legislative Bill. Entered into effect on 1 July 1998, with the exception
More informationSaving for children:
Saving for children: A baseline survey at the inception of the Child Trust Fund Executive Summary Elaine Kempson, Adele Atkinson and Sharon Collard Personal Finance Research Centre University of Bristol
More informationFebruary 3, Experience Study Judges Retirement Fund
February 3, 2012 Experience Study 2007-2011 February 3, 2012 Minnesota State Retirement System St. Paul, MN 55103 2007 to 2011 Experience Study Dear Dave: The results of the actuarial valuation are based
More informationDisclosure Methodological Note For Aventis Pharma Ltd trading as Sanofi
Disclosure 2015 Methodological Note For Aventis Pharma Ltd trading as Sanofi INTRODUCTION The EFPIA Disclosure Code requires all EFPIA member companies to disclose transfers of value (TOV) such as support
More informationFinancial Management in the Department for Children, Schools and Families
Financial Management in the Department for Children, Schools and Families LONDON: The Stationery Office 14.35 Ordered by the House of Commons to be printed on 28 April 2009 REPORT BY THE COMPTROLLER AND
More informationTime limiting contributory Employment and Support Allowance to one year for those in the work-related activity group
Time limiting contributory Employment and Support Allowance to one year for those in the work-related activity group Equality Impact Assessment March 2011 Equality impact assessment for time limiting contributory
More informationThe UK debate on the funding of
The UK debate on the funding of long term care services Jose-Luis Fernandez PSSRU, London School of Economics PSSRU International conference on the policies and regulations governing the costs of health
More informationIMS Brogan Private Drug Plan Drug Cost Forecast Commissioned by Rx&D Canada s Research-Based Pharmaceutical Companies
IMS Brogan Private Drug Plan Drug Cost Forecast 2013-2017 Commissioned by Rx&D Canada s Research-Based Pharmaceutical Companies Overview 1. Who are Rx&D and IMS Brogan? 2. Environment 3. Background 4.
More informationAmendments to payment on account provisions. Equality impact assessment March 2011
Amendments to payment on account provisions Equality impact assessment March 2011 Equality impact assessment for amendment to payment on account provisions Outline of the existing policy 1. Section 5(1)(r)
More informationThe use of linked administrative data to tackle non response and attrition in longitudinal studies
The use of linked administrative data to tackle non response and attrition in longitudinal studies Andrew Ledger & James Halse Department for Children, Schools & Families (UK) Andrew.Ledger@dcsf.gsi.gov.uk
More informationSubmitted by NHS Employers
Response to Her Majesty's Treasury s( HMT ) consultation on draft directions titled The Public Service Pensions (Valuations and Employer Cost Cap) Directions 2013 (the valuation directions ) Submitted
More informationGENDER EQUITY IN THE TAX SYSTEM FOR FISCAL SUSTAINABILITY
GENDER EQUITY IN THE TAX SYSTEM FOR FISCAL SUSTAINABILITY Workshop: Gender Equity in Australia s Tax and Transfer System 4-5 November 2015 Patricia Apps University of Sydney Law School and IZA Introduction
More informationPublic Health England s grant to local authorities
Report by the Comptroller and Auditor General Department of Health and Public Health England Public Health England s grant to local authorities HC 888 SESSION 2014-15 17 DECEMBER 2014 4 Key facts Public
More informationCullen Wealth guides. How grandparents can help their grandchildren with their finances
How grandparents can help their grandchildren with their finances Introduction The natural order of events suggests that wealth tends to accumulate throughout a working life and into retirement. This pattern
More informationUniversal access to health and care services for NCDs by older men and women in Tanzania 1
Universal access to health and care services for NCDs by older men and women in Tanzania 1 1. Background Globally, developing countries are facing a double challenge number of new infections of communicable
More informationAppendix CA-15. Central Bank of Bahrain Rulebook. Volume 1: Conventional Banks
Appendix CA-15 Supervisory Framework for the Use of Backtesting in Conjunction with the Internal Models Approach to Market Risk Capital Requirements I. Introduction 1. This Appendix presents the framework
More informationMyrskyläntie 16 mobile +358 (0) Helsinki Finland
1 TAX JUSTICE RESEARCH WORKSHOP Nairobi 18th - 19th JAN2007 Kati Peltola kati.peltola@kolumbus.fi Myrskyläntie 16 mobile +358 (0)50 563 23 14 00600 Helsinki Finland PROMOTING PRO-POOR DEVELOPMENT Transparent
More informationTEN PRICE CAP RESEARCH Summary Report
TEN-16-075. PRICE CAP RESEARCH Summary Report Prepared for: Financial Conduct Authority 25 The North Colonnade Canary wharf London E14 16 June 2017 Table of Contents 1. Introduction... 2 1.1 Background...
More informationWales Patient Access Scheme: Process Guidance
Wales Patient Access Scheme: Process Guidance July 2012 (Updated August 2016) This guidance document has been prepared by the Patient Access Scheme Wales Group, with support from the All Wales Therapeutics
More informationPRESCRIPTION MEDICINE PRICING OUR PRINCIPLES AND PERSPECTIVES
PRESCRIPTION MEDICINE PRICING OUR PRINCIPLES AND PERSPECTIVES We at Sanofi work passionately, every day, to understand and solve health care needs of people across the world. We are dedicated to therapeutic
More informationRisk Management Strategy
Risk Management Strategy 2016 2019 Version: 6 Policy Lead/Author & Deputy Director of Quality position: Ward / Department: Nursing Directorate Replacing Document: Version 5 Approving Committee Quality
More informationHEALTH AND WELLBEING: AGEING WORKFORCE
HEALTH AND WELLBEING: AGEING WORKFORCE DR NATHAN LANGSLEY BMEDSCI, MB BS, MRCPSYCH, MPHIL Welcome My details Scope of the talk Apologies for terminology eg older or ageing Apologies that some stats (eg
More informationJanuary 13, Submitted electronically Secretary Brent J. Fields U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C.
January 13, 2016 Submitted electronically Secretary Brent J. Fields U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: File No. S7-16-15 Open-End Fund Liquidity Risk
More informationKEY GUIDE. Pensions tax planning for high earners
KEY GUIDE Pensions tax planning for high earners The rising tax burden on income If you are a high-earner and feel you are paying more and more tax, you are not alone. More than one in seven income tax
More informationThe consequences of uncertainty and the implications for policy. Karl Claxton 21/11/2017
The consequences of uncertainty and the implications for policy Karl Claxton 21/11/2017 Overview Why does uncertainty matter? Clinical value of evidence Linking endpoints to outcome Dealing with costs
More informationPre Budget Submission 2010:
Pre Budget Submission 2010: Introduction: Respond! is Ireland's largest not for profit Housing Association. We seek to create a positive future for people by alleviating poverty and creating vibrant, socially
More informationBackground The Health Impact Fund (HIF) Characteristics of the HIF Progress
1 Background The Health Impact Fund (HIF) Characteristics of the HIF Progress 2 Millions of patients lack access to the optimal medicines because of high prices made possible by patent protection. Low
More informationDEPARTMENT OF EDUCATION EQUALITY AND HUMAN RIGHTS POLICY SCREENING FOR INVESTING IN THE TEACHING WORKFORCE SCHEME, 2016/17 (PILOT)
DEPARTMENT OF EDUCATION EQUALITY AND HUMAN RIGHTS POLICY SCREENING FOR INVESTING IN THE TEACHING WORKFORCE SCHEME, 2016/17 (PILOT) Teachers Negotiating Team 028 9127 9349 (Ext 59349) Further advice on
More informationWhat is the problem under consideration? Why is government intervention necessary?
Title: Disability Living Allowance Reform Lead department or agency: Department for Work and Pensions Other departments or agencies: Impact Assessment (IA) IA No: Date: October 2011 Stage: Final Source
More informationImportant changes and information
Important changes and information September 2017 A summary of the significant changes in the recent Federal Budgets. Federal Budget 2017/18: incentives to invest in superannuation The two main measures
More informationMethodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur
Methodological Note to 2017 Disclosure Report for Aventis Pharma Limited Genzyme Therapeutics Limited and Sanofi Pasteur Job Bag: SAGB.SA.18.03.0294 Date of Preparation: March 2018 INTRODUCTION The European
More informationThe impact of a tightening fiscal situation on social care for older people
The impact of a tightening fiscal situation on social care for older people Julien Forder and José-Luis Fernández PSSRU Discussion Paper 2723 May 2010 www.pssru.ac.uk/pdf/dp2723.pdf The authors would like
More informationRisk Management Strategy January NHS Education for Scotland RISK MANAGEMENT STRATEGY
NHS Education for Scotland RISK MANAGEMENT STRATEGY January 2016 1 Contents 1. NES STATEMENT ON RISK MANAGEMENT 2 RISK MANAGEMENT STRATEGY 3 RISK MANAGEMENT STRUCTURES 4 RISK MANAGEMENT PROCESSES 5 RISK
More informationCare Quality Commission consultation on regulatory fees from April 2018: NHS Providers response
17 January 2018 Care Quality Commission consultation on regulatory fees from April 2018: NHS Providers response About NHS Providers NHS Providers is the membership organisation and trade association for
More informationHousing Commission Report
Housing Commission Report To: From: Subject: Housing Commission Meeting: April 20, 2017 Agenda Item: 5B Chair and Housing Commission Barbara Collins, Housing Manager Preserving Our Diversity (POD) Subsidy
More information8: Economic Criteria
8.1 Economic Criteria Capital Budgeting 1 8: Economic Criteria The preceding chapters show how to discount and compound a variety of different types of cash flows. This chapter explains the use of those
More informationNATIONAL PERSONAL BUDGETS SURVEY Summary of main findings and next steps
NATIONAL PERSONAL BUDGETS SURVEY 2013 Summary of main findings and next steps Authors: Chris Hatton, Centre for Disability Research at Lancaster University, John Waters, In Control and Martin Routledge,
More informationIntroduction of Health Economics
Introduction of Health Economics Prof. Jie Chen Health Technology Assessment & Research Center Fu Dan University 4 th March, 2004 Outline Why economics for healthcare services? Some basic economic concepts
More informationCosts to Britain of workplace injuries and work-related ill health: 2009/10 update
Health and Safety Executive Costs to Britain of workplace injuries and work-related ill health: 2009/10 update Workplace fatalities and self reported injury and ill health Contents Summary 3 Introduction
More informationNHS Working Longer Group Initial findings and recommendations. What do they say about older women at work?
NHS Working Longer Group Initial findings and recommendations What do they say about older women at work? Background The Working Longer Group (WLG) was established to address the impact of a raised retirement
More informationEUROPEAN COMMISSION EUROSTAT. Directorate F: Social statistics Unit F-5: Education, health and social protection
EUROPEAN COMMISSION EUROSTAT Directorate F: Social statistics Unit F-5: Education, health and social protection DOC 2013-PH-06 Annex 6D Towards a possible Out of Pocket (OOP) expenditure Indicator at macro-level
More information